The proposed acquisition will bolster Sartorius' position in downstream bioprocessing and build upon the companies' research and development partnership. Novasep and Sartorius have been working since 2018 on an optimized system for membrane-based low-pressure chromatography that processes larger molecules more productively. A product is expected to be launched soon.

The companies agreed not to disclose the purchase price until necessary regulatory approvals have been obtained. The transaction is expected to close during the first half of 2021.

Sartorius acquires WaterSep BioSeparations
Sartorius Stedim Biotech has acquired WaterSep BioSeparations for approximately $27 million plus an earn-out based on sales revenues through 2023...

Sensorion, Novasep ink gene therapy agreement
Sensorion and Novasep have signed an agreement for the manufacturing of adeno-associated virus vectors covering a gene therapy program that targets OTOF,...

Novasep, Lysogene partner for gene therapy
Novasep and Lysogene announced that the parties have inked an agreement for the development and manufacturing of an adeno-associated viral vector-based...